A composition containing salidroside and its use in the preparation of a product for protecting the cardiovascular system and / or repairing myocardial damage

Abstract

The application provides a composition which comprises at least ergothioneine, rhodioloside and coenzyme Q10 in a physiologically acceptable medium, and the three substances in the composition are synergistically compounded to achieve the effect of significantly repairing myocardial injury and protecting cardiovascular.

Description

Technical Field

[0001] This application relates to the field of oral product technology, specifically to a composition comprising ergothioneine, rhodioloside and coenzyme Q10 and its use. Background Technology

[0002] Myocardial injury, a core link in the cardiovascular event chain, refers to the necrosis or apoptosis of myocardial cells due to various causes. Essentially, it involves the release of intracellular specific markers (such as cardiac troponin) into the bloodstream. The inducing factors for this injury are extremely broad and can be categorized into several key pathways: the most classic is ischemic injury, represented by acute myocardial infarction, originating from acute occlusion of the coronary arteries; secondly, supply-demand imbalance injury occurs when the cardiac workload increases dramatically (e.g., rapid arrhythmias, severe hypertension) or blood supply is insufficient (e.g., hypotension, anemia); in addition, direct myocardial injury should not be ignored, including myocarditis, cardiac contusion, and the cardiotoxicity of certain chemotherapy drugs; finally, excessive cardiac load (e.g., acute heart failure, severe valvular disease) and systemic diseases (e.g., sepsis, renal failure) are also common contributing factors.

[0003] Myocardial injury is often the acute trigger point for cardiovascular diseases, such as acute myocardial infarction. On the other hand, each injury initiates a pathological remodeling process in the heart—functional myocardium is replaced by non-contractile scar tissue, leading to cardiac enlargement and deformation, a continuous decline in pumping function, and ultimately driving the irreversible progression of the disease to chronic heart failure. Therefore, even a minor, asymptomatic myocardial injury is a strong warning sign of future major adverse cardiovascular events. These events share common risk factors such as hypertension, diabetes, and smoking, forming a complete pathological chain from risk factors to myocardial injury, and then to heart failure and death.

[0004] Actively controlling risk factors and protecting myocardial cells from the source is crucial for breaking this vicious cycle and improving long-term cardiovascular prognosis.

[0005] Rhodioloside is the core active ingredient in the traditional medicinal plant Rhodiola rosea. It can activate the body's endogenous defense mechanism, the Nrf2 signaling pathway, and enhance the cell's ability to resist oxidative stress. Simultaneously, it can effectively inhibit key inflammatory pathways such as NF-κB, reducing cytokine storms. Ergothioneine is a naturally occurring amino acid derivative with specific transport proteins that can be efficiently concentrated in mitochondria. Coenzyme Q10 is a naturally occurring fat-soluble quinone in the human body that directly participates in the synthesis of adenosine triphosphate (ATP), providing the basic fuel for the continuous contraction and relaxation of the heart. Currently, there are many types of cardiovascular health products on the market, but their actual effects vary. Summary of the Invention

[0006] To address the technical problem of insufficient cardiovascular protection in existing technologies, this application provides a composition containing ergothioneine, rhodioloside, and coenzyme Q10. The synergistic combination of these three substances in the composition can achieve significant repair of myocardial damage and protection of the cardiovascular system.

[0007] The specific technical solution of this application is as follows: 1. A composition comprising at least ergothioneine, rhodioloside and coenzyme Q10 in a physiologically acceptable medium.

[0008] 2. The composition according to item 1, wherein the mass ratio of ergothioneine, rhodioloside and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

[0009] 3. The composition according to claim 1 or 2, wherein the composition further comprises excipients.

[0010] 4. The composition according to any one of items 1-3, wherein the dosage form of the composition is tablets, powders, granules, capsules or aqueous solutions.

[0011] 5. Use of the composition of any one of items 1-4 in the preparation of products for protecting the cardiovascular system and / or repairing myocardial damage.

[0012] 6. Use of ergothioneine, rhodioloside and coenzyme Q10 in the preparation of products for the protection of the cardiovascular system and / or the repair of myocardial damage.

[0013] 7. According to the use described in item 6, wherein the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

[0014] 8. An article for protecting the cardiovascular system and / or repairing myocardial damage, comprising the composition described in any one of items 1-4.

[0015] Beneficial effects (1) The composition provided in this application contains ergothionein, rhodioloside and coenzyme Q10. The three are combined and have a synergistic effect, which can repair myocardial damage and protect the cardiovascular system.

[0016] (2) The raw materials used in this application, ergothioneine and rhodioloside, are both fermentation-derived and have high safety.

[0017] (3) The production cost of this application is low, the process cycle is short, the pollution is small, the energy consumption is low, and it is easy to industrialize. Detailed Implementation

[0018] The present application will now be described in detail with reference to the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this application will be thorough and complete, and will fully convey the scope of the present application to those skilled in the art.

[0019] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.

[0020] This application provides a composition comprising ergothioneine, rhodioloside, and coenzyme Q10.

[0021] The ergothioneine, rhodioloside, and coenzyme Q10 in the composition of this application have a synergistic effect, which can repair myocardial damage and protect the cardiovascular system.

[0022] The coenzyme Q10 comprises reduced coenzyme Q10 and oxidized coenzyme Q10. In this application, the coenzyme Q10 may be reduced coenzyme Q10, oxidized coenzyme Q10, or a mixture of oxidized Q10 and reduced coenzyme Q10 in any proportion.

[0023] In some embodiments, the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

[0024] For example, the mass ratios of ergothioneine, rhodioloside, and coenzyme Q10 are 1:0.25:0.3, 1:0.25:0.4, 1:0.25:0.5, 1:0.25:0.6, 1:0.25:0.7, 1:0.25:0.8, 1:0.25:0.9, 1:0.25:1, 1:0.25:2, 1:0.25:3, 1:0.25:4, 1:0.25:5, 1 :0.25:6, 1:0.25:7, 1:0.25:8, 1:0.25:9, 1:0.25:10, 1:0.25:11, 1:0.25:12, 1:0.25:13, 1:0.25:14, 1:0.25:15, 1:0.25:16, 1:0.25:17, 1:0.25:18, 1:0.25:19, 1:0.25:20, 1: 0.25:21, 1:0.25:22, 1:0.25:23, 1:0.25:24, 1:0.25:25, 1:0.25:26, 1:0.25:27, 1:0.25:28, 1:0.25:29, 1:0.25:30, 1:0.3:1, 1:0.4:1, 1:0.5:1, 1:0.6:1, 1:0.7:1, 1:0.8:1, 1 :0.9:1, 1:1:1, 1:2:1, 1:3:1, 1:4:1, 1:5:1, 1:6:1, 1:7:1, 1:8:1, 1:9:1, 1:10:1, 1:11:1, 1:12:1, 1:13:1, 1:14:1, 1:15:1, 1:16:1, 1:17:1, 1:18:1, 1:19:1, 1:20:1, etc., or any range thereof.

[0025] More preferably, the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(0.5-10):(0.5-20).

[0026] For example, the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(1-10):(1-20), 1:(1-10):(10-20), 1:(2-8):(12-18), 1:(0.5-1.5):(0.5-1.5), 1:(0.25-10):(0.25-10), 1:(1-5):(1-5), 1:(0.5-2):(0.5-10), 1:(1-2):(1-10), 1:(0.25-1.5):(0.5-1.5).

[0027] In this application, no restrictions are placed on the mass percentage of ergothioneine, rhodioloside and coenzyme Q10 in the composition, as long as the requirements of this application are met.

[0028] In some embodiments, the composition further comprises excipients.

[0029] In this application, no restrictions are placed on the excipients. Those skilled in the art can use conventionally used excipients, such as fillers, disintegrants, lubricants, flavoring agents, etc.

[0030] In this application, no restrictions are placed on the content of excipients in the composition, and those skilled in the art can choose the amount of excipients to be added based on actual needs.

[0031] In some embodiments, the dosage form of the composition is tablets, powders, granules, capsules, or liquids.

[0032] In this application, no restrictions are placed on the preparation methods of the dosage forms mentioned herein. Those skilled in the art can choose conventionally used methods in the field to prepare the tablets based on actual needs. For example, tablets can be prepared by mixing ergothioneine, rhodioloside, coenzyme Q10, and optional excipients, followed by wet granulation, drying, and compression to obtain tablets.

[0033] The powder can be prepared by mixing ergothioneine, rhodioloside, coenzyme Q10, and optional excipients, sieving, sterilizing and packaging. Granules can be prepared by mixing ergothioneine, rhodioloside, coenzyme Q10, and optional excipients, followed by one-step granulation, sterilization, and packaging. Capsule formulation can be produced through a process of raw material pretreatment, weighing and mixing, premixing, granulation, total mixing, filling, polishing, and packaging. Aqueous solutions can be prepared by pretreatment of raw materials and auxiliary materials, followed by dissolution, filtration, filling, sterilization, and packaging.

[0034] In this application, the composition described herein can be administered orally.

[0035] This application provides for the use of the compositions described in any of the above claims in the preparation of products for protecting the cardiovascular system and / or repairing myocardial damage.

[0036] The composition described in this application can increase blood flow velocity and cardiac output, and reduce the fluorescence intensity of apoptotic cardiac cells, and therefore can be used to protect the cardiovascular system and / or repair myocardial damage.

[0037] This application provides the use of ergothioneine, rhodioloside, and coenzyme Q10 in the preparation of products for protecting the cardiovascular system and / or repairing myocardial damage. In some embodiments, the mass ratio of ergothioneine, rhodioloside, and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

[0038] For example, the mass ratios of ergothioneine, rhodioloside, and coenzyme Q10 are 1:0.25:0.3, 1:0.25:0.4, 1:0.25:0.5, 1:0.25:0.6, 1:0.25:0.7, 1:0.25:0.8, 1:0.25:0.9, 1:0.25:1, 1:0.25:2, 1:0.25:3, 1:0.25:4, 1:0.25:5, 1 :0.25:6, 1:0.25:7, 1:0.25:8, 1:0.25:9, 1:0.25:10, 1:0.25:11, 1:0.25:12, 1:0.25:13, 1:0.25:14, 1:0.25:15, 1:0.25:16, 1:0.25:17, 1:0.25:18, 1:0.25:19, 1:0.25:20, 1: 0.25:21, 1:0.25:22, 1:0.25:23, 1:0.25:24, 1:0.25:25, 1:0.25:26, 1:0.25:27, 1:0.25:28, 1:0.25:29, 1:0.25:30, 1:0.3:1, 1:0.4:1, 1:0.5:1, 1:0.6:1, 1:0.7:1, 1:0.8:1, 1 :0.9:1, 1:1:1, 1:2:1, 1:3:1, 1:4:1, 1:5:1, 1:6:1, 1:7:1, 1:8:1, 1:9:1, 1:10:1, 1:11:1, 1:12:1, 1:13:1, 1:14:1, 1:15:1, 1:16:1, 1:17:1, 1:18:1, 1:19:1, 1:20:1, etc., or any range thereof.

[0039] More preferably, the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(0.5-10):(0.5-20).

[0040] For example, the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(1-10):(1-20), 1:(1-10):(10-20), 1:(2-8):(12-18), 1:(0.5-1.5):(0.5-1.5), 1:(0.25-10):(0.25-10), 1:(1-5):(1-5), 1:(0.5-2):(0.5-10), 1:(1-2):(1-10), 1:(0.25-1.5):(0.5-1.5).

[0041] This application provides an article for protecting the cardiovascular system and / or repairing myocardial damage, comprising the composition described in any one of the above claims.

[0042] In this application, no restrictions are placed on the percentage of the composition in the article by mass, and those skilled in the art can make conventional choices based on actual needs.

[0043] Example This application provides a general and / or specific description of the materials and methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. All reagents and instruments used, unless otherwise specified, are commercially available conventional products. Rhodioloside and ergothioneine (EGT) were sourced from Bloomage Biotechnology Co., Ltd., and Coenzyme Q10 was sourced from Kingway, specifically oxidized Coenzyme Q10 derived from microbial fermentation.

[0044] Preparation of powders in Examples 1-7 (1) Mixing: Ergothioneine (EGT), rhodioloside and coenzyme Q10 are mixed together. The total mass of the three substances is 100g. The ratio of the three substances is shown in Table 1.

[0045] (2) Sieving: Pass the evenly mixed material through a 60-mesh Taylor standard sieve to obtain a uniform powder. (3) Sterilization: The material obtained in step (2) is sterilized by ultraviolet light for 30 minutes; (4) Packaging: The sterilized material is packaged in bags of 2.5g each.

[0046] Example 8: Preparation of Tablets (1) Mixing: Ergothioneine (EGT), rhodioloside and coenzyme Q10 are mixed evenly with the excipients; wherein, the mass ratio of ergothioneine (EGT), rhodioloside and coenzyme Q10 is 1:8:15, the total mass of ergothioneine (EGT), rhodioloside and coenzyme Q10 is 42g, and the excipients are composed of 50g of microcrystalline cellulose, 7.8g of magnesium stearate and 0.2g of silicon dioxide; (2) Tableting: The mixed materials are compressed to obtain 80 tablets, each weighing 1.0g.

[0047] Example 9 Preparation of Granules (1) Mixing: Ergothioneine (EGT), rhodioloside and coenzyme Q10 are mixed evenly with the excipients, wherein the mass ratio of ergothioneine (EGT), rhodioloside and coenzyme Q10 is 1:5:10; wherein the total mass of ergothioneine (EGT), rhodioloside and coenzyme Q10 is 1 kg. (2) One-step granulation: After mixing evenly, add it to an FBM-3 type fluidized bed granulator (equipment capacity is 3L). Use 30wt% aqueous solution containing ethanol as wetting agent and spray it from the top of the fluidized bed granulator. The atomization pressure of the fluidized bed granulator is 0.1MPa and the air inlet temperature is 60℃. After processing for 84min, use 20 mesh and 60 mesh sieves to screen and obtain particles between 60 mesh and 80 mesh. (3) Sterilization: The material obtained in step (2) is sterilized by ultraviolet light for 30 minutes; (4) Packaging: The sterilized material is packaged to obtain 180 bags of granules, each bag containing 5g.

[0048] Comparative Example 1: Preparation of Powder 100g of ergothioneine (EGT) was sterilized by ultraviolet light for 30 minutes and then packaged in aluminum foil bags, with each bag containing 2.5g, as shown in Table 1.

[0049] Comparative Example 2: Preparation of Powder 100g of rhodioloside was sterilized by ultraviolet light for 30 minutes and then packaged in aluminum foil bags, with each bag containing 2.5g, as shown in Table 1.

[0050] Comparative Example 3: Preparation of Powder 100g of Coenzyme Q10 is sterilized by ultraviolet light for 30 minutes and then packaged in aluminum foil bags, with each bag containing 2.5g, as shown in Table 1.

[0051] Preparation of powders in comparative examples 4 to 6 (1) Mixing: Ergothioneine (EGT), rhodioloside and coenzyme Q10 are mixed in pairs. The total mass of the two substances is 100g. The ratio of the two substances is shown in Table 1. (2) Sieving: Pass the evenly mixed material through a 60-mesh Taylor standard sieve to obtain a uniform powder. (3) Sterilization: The material obtained in step (2) is sterilized by ultraviolet light for 30 minutes; (4) Packaging: The sterilized material is packaged in bags of 2.5g each.

[0052] Table 1

[0053] Note: "-" indicates that the corresponding component was not added; "√" indicates that the corresponding component was added.

[0054] Evaluation of the cardiovascular protective efficacy of experimental cases Around 16 hpf, zebrafish cardiac progenitor cells begin to differentiate. After reaching the midline, these progenitor cells interconnect, a process that leads to cardiac fusion. Following fusion, the cardiac cone extends, gradually transforming into a linear cardiac tube around 24 hpf. This is similar to mammals, where, after gastrulation, bilateral cardiac progenitor cells migrate to the midline to form a single cardiac tube. Then, the left side coils to form the anatomical atria, ventricles, and atrioventricular valves. While zebrafish lack septa within their atria and ventricles, they share a high degree of genetic similarity with mammals in cardiac formation. The zebrafish heart possesses both β1 and β2 receptors and is structurally and functionally very similar to the human adrenergic β-receptor gene. Isoproterenol, a non-selective adrenergic β-receptor agonist, acts on cardiac β1 receptors, increasing heart rate, causing sustained and strong myocardial contraction, and increasing cardiac output and myocardial oxygen consumption. This leads to a shift from compensatory to decompensatory contraction, resulting in arrhythmias, myocardial ischemia and necrosis, ultimately causing heart failure. Zebrafish with a 48hpf heart rate have a sensitive cardiovascular system, making them suitable for establishing cardiovascular protection models.

[0055] I. Experimental Methods Different samples were obtained using the powders prepared in Examples 1-7 and Comparative Examples 1-6 as solutes and standard dilution water as solvents.

[0056] Zebrafish strain: All zebrafish are raised in aquarium water at 28℃ (water quality: 200mg of instant sea salt added per 1L of reverse osmosis water, conductivity 450~550 μS / cm; pH 6.5~8.5; hardness 50~100 mg / L CaCO3), bred and provided by our company's aquarium. The laboratory animal use license number is: SYXK (Zhejiang) 2022-0004. The breeding and management meet the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2025-12291-01.

[0057] Dissecting microscope (SZX7, OLYMPUS); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd.); motorized focusing continuous zoom fluorescence microscope (AZ100, Nikon); precision electronic balance (CP214, OHAUS); 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd.).

[0058] Dimethyl sulfoxide (DMSO, batch number BCCD8942, Sigma); Methylcellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd.); Isoproterenol hydrochloride (batch number VZXJK-JR, TCI (Shanghai) Chemical Industry Development Co., Ltd.); Acridine orange (batch number C15687307, Shanghai Maclean Biochemical Technology Co., Ltd.).

[0059] II. Observation and Measurement 2.1. Evaluation of cardiovascular protective efficacy - fluorescence intensity of apoptotic myocardial cells Two dpf wild-type AB strain zebrafish were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. Different samples were administered water-soluble solutions. The positive control was given Compound Danshen Dripping Pills at a concentration of 62.5 μg / mL. Normal control and model control groups were also set up, with a volume of 3 mL per well. Except for the normal control group, all other experimental groups were given water-soluble isoproterenol hydrochloride to establish a zebrafish myocardial injury model. After treatment at 28℃ for 5 h, acridine orange (AO) staining was performed. Subsequently, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were acquired using NIS-Elements D 3.20 advanced image processing software, and the fluorescence intensity of apoptotic cells in zebrafish myocardium was analyzed. The cardiovascular protective efficacy of the samples was evaluated based on the statistical analysis results of this index. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0060] 2.2. Evaluation of Cardiovascular Protective Efficacy - Cardiac Output and Blood Flow Velocity Two dpf wild-type AB strain zebrafish were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. Samples were administered via water-soluble solution. A positive control was administered compound Danshen dripping pills at a concentration of 62.5 μg / mL. A normal control group and a model control group were also set up, with a volume of 3 mL per well. Except for the normal control group, all other experimental groups were administered isoproterenol hydrochloride via water-soluble solution to establish a zebrafish myocardial injury model. After treatment at 28℃ for 5 h, 10 zebrafish from each experimental group were randomly selected and video-recorded using a cardiac blood flow analysis system. Cardiac output and blood flow velocity were analyzed, and the cardiovascular protective efficacy of the samples was evaluated based on statistical analysis of these indicators. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0061] III. Experimental Results and Analysis The cardiovascular protective effects are shown in Table 2.

[0062] Table 2 Results of the cardiovascular protective efficacy of the samples

[0063] * indicates comparison with the model control group (between two groups), *p<0.05, **p<0.01, ***p<0.001 As can be seen from the table above, under the experimental conditions, the three parameters showed a consistent trend. The combination of ergothionein, rhodioloside, and coenzyme Q10 showed better cardiovascular protection, specifically manifested in decreased fluorescence intensity of zebrafish cardiac apoptotic cells, increased blood flow velocity, and increased cardiac output. It can be seen that the average fluorescence intensity of zebrafish cardiac apoptotic cells in each group of the examples was lower than that of the model control group, the average blood flow velocity was higher than that of the model control group, and the cardiac output was higher than that of the model control group, and the results showed significant differences.

[0064] The average fluorescence intensity, blood flow velocity, and cardiac output of apoptotic cells in the hearts of zebrafish in each group were analyzed.

[0065] (1) Comparing Example 4 with Comparative Examples 1-6, the efficacy of ergothioneine, rhodioloside, and coenzyme Q10 in combination with single components and in pairs was examined. The total amount of active ingredients in each group was consistent. The results are shown in Table 3. As can be seen from Table 3, the positive control group and Example 4 showed comparable cardiovascular protection effects, with no significant differences in cardiac apoptotic cell fluorescence intensity, blood flow velocity, and cardiac output. Under the premise of consistent total amount of active ingredients, the cardiac apoptotic cell fluorescence intensity, blood flow velocity, and cardiac output of the ergothioneine, rhodioloside, and coenzyme Q10 combination were significantly better than those of the single component and the pairwise combination groups, indicating that the combination of the three components had a synergistic effect.

[0066] Table 3. Cardiovascular protective effects of the combination of ergothioneine, rhodioloside, and coenzyme Q10

[0067] * indicates comparison with Example 4 (between two groups), *p<0.05, **p<0.01, ***p<0.001 (2) Examples 1-7 were compared with Comparative Examples 1-3 respectively. The results are shown in Table 4. As can be seen from Table 4, under the premise of consistent total efficacy, the cardiovascular protection efficacy of Examples 1-3 was not significantly different from that of the single-component group Comparative Examples 1-3 in terms of cardiac apoptosis cell fluorescence intensity data, and the cardiovascular protection efficacy was significantly lower than that of the positive control group. However, the cardiovascular protection efficacy of Examples 4-7 was better than that of the single-component group Comparative Examples 1-3, and the data showed significant differences. The cardiovascular protection efficacy was comparable to that of the positive control group.

[0068] Table 4. Cardiovascular protective effects of ergothioneine, rhodioloside, and coenzyme Q10

[0069] a indicates a comparison with Comparative Example 1 (between two groups) *p < 0.05; b indicates a comparison with Comparative Example 2 (between two groups) *p < 0.05; c indicates a comparison with Comparative Example 3 (between two groups) *p<0.05; d indicates a comparison with the positive control group (between two groups) *p<0.05 As shown in Table 4, when the mass ratio of ergothioneine, rhodioloside, and coenzyme Q10 in the composition described in this application is 1:0.25-20:0.3-30, the composition is more effective than the single-dose group and the pairwise combination group of ergothioneine, rhodioloside, and coenzyme Q10, showing a synergistic effect. It can significantly reduce the fluorescence intensity of apoptotic cardiac cells and increase blood flow velocity and cardiac output, that is, it has a significant protective effect on the cardiovascular system.

[0070] In summary, the three substances in the composition described in this application have a synergistic effect, which can significantly reduce the fluorescence intensity of apoptotic cardiac cells and improve blood flow velocity and cardiac output, thus having a significant protective effect on the cardiovascular system.

[0071] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.

Claims

1. A composition comprising at least ergothioneine, rhodioloside and coenzyme Q10 in a physiologically acceptable medium.

2. The composition according to claim 1, wherein the mass ratio of ergothioneine, rhodioloside and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

3. The composition according to claim 1 or 2, wherein the composition further comprises excipients.

4. The composition according to any one of claims 1-3, wherein the dosage form of the composition is tablets, powders, granules, capsules or aqueous solutions.

5. Use of the composition of any one of claims 1-4 in the preparation of products for protecting the cardiovascular system and / or repairing myocardial damage.

6. Use of ergothioneine, rhodioloside and coenzyme Q10 in the preparation of products for the protection of the cardiovascular system and / or the repair of myocardial damage.

7. The use according to claim 6, wherein the mass ratio of ergothionein, rhodioloside and coenzyme Q10 is 1:(0.25-20):(0.3-30), preferably 1:(0.25-10):(0.5-20).

8. An article for protecting the cardiovascular system and / or repairing myocardial damage, comprising the composition of any one of claims 1-4.

Images